JAGSNPHARM and ZIMLAB, both in Pharmaceuticals: Generic. Monthly data through 2026-10-09. Change the comparison →
Share price change since Nov '22, the first month all 2 have a price: JAGSNPHARM +76%, ZIMLAB +43%.
Rebased at 2022-11. Monthly closes from each company's history.
Months with a missing value are left as gaps.
The share price return over 3 years, split into net profit growth, share count change and the change in P/E.
JAGSNPHARM: share price rose 39% over 3 years: +63 pts from net profit growth, −22 pts from the P/E change, −2 pts from share count change.
ZIMLAB: share price rose 29% over 3 years: −215 pts from net profit growth, +244 pts from the P/E change, +1 pts from share count change.
Segments are percentage points of the price return: price = P/E × net profit ÷ share count. These are the same numbers each company's own page shows.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | JAGSNPHARM | ZIMLAB |
|---|---|---|
| Share Price | ₹225.60 | ₹150.47 |
| Market Cap | ₹1517 cr | ₹729 cr |
| P/E | 33.0x | 192.9x |
| P/B | 5.5x | 2.5x |
| P/S | 5.2x | 1.9x |
| ROCE | 23.0% | 5.0% |
| ROE | 16.7% | 1.3% |
| Operating margin | 21.0% | 2.6% |
| Revenue (TTM), indexed to 100 | ₹293 cr | ₹392 cr |
| Net Profit (TTM) | ₹46 cr | ₹4 cr |
| Debt / Equity | 0.0x | 0.4x |
| Cash Conversion Cycle | 33d | 129d |
| Promoter holding | 69.1% | 30.4% |
| FII Holding | 2.3% | 0.0% |
| DII Holding | 0.6% | 1.3% |
| 12M momentum | 1.2% | 105.5% |
| Drawdown from Peak | -25.9% | 0.0% |
| Cash conversion (3Y) | 1.1x | 3.1x |
| Interest cover | — | 1.4x |
| Share Count Change (1Y) | 0.0% | 10.2% |
| Volatility (1Y) | 32.1% | 50.5% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.